Vistin Pharma ASA (DE:VP4) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vistin Pharma ASA reports a stable second quarter in 2024 with a slight increase in revenue to MNOK 106, up from MNOK 107 in the same quarter of the previous year. EBITDA surged by 40% to MNOK 27, attributed to improved product mix and cost control. The company also announced a cash dividend of NOK 0.50 per share distributed in June, with an additional dividend planned for Q4.
For further insights into DE:VP4 stock, check out TipRanks’ Stock Analysis page.